Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467

Subject indexing assigned by NLM

Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal /therapeutic use; Breast Neoplasms /drug therapy /mortality /therapy; Carrier Proteins /analysis; Chemotherapy, Adjuvant; Colorectal Neoplasms /epidemiology; Endometrial Neoplasms /epidemiology; Female; Humans; Incidence; Menopause; Middle Aged; Neoplasm Recurrence, Local /epidemiology; Receptors, Estrogen /analysis; Survival Rate; Tamoxifen /therapeutic use; Time Factors

11998008598

16/05/2008

This article is related to a Cochrane Protocol or Review which is published in the Cochrane Database of Systematic Reviews where it will be regularly updated. Cochrane Reviews are of a high standard and are not evaluated by CRD. The link is:

http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000486/frame.html

The editorial team have withdrawn this review ‘Tamoxifen for early breast cancer’ from publication since the most up-to-date results from the Early Breast Cancer Trialists' Collaborative Group overview are available from the Clinical Trial Service Unit and Epidemiological Studies Unit website (http://www.ctsu.ox.ac.uk/projects/ebctcg/).